Trevi Therapeutics Inc (TRVI)

NASDAQ
1.330
+0.110(+9.02%)
Pre Market
1.330
0.000(0.00%)
- Real-time Data
  • Volume:
    777,222
  • Bid/Ask:
    1.250/1.350
  • Day's Range:
    1.220 - 1.360

TRVI Overview

Prev. Close
1.22
Day's Range
1.22-1.36
Revenue
-
Open
1.25
52 wk Range
1.1-3.975
EPS
-1.84
Volume
777,222
Market Cap
29.27M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
363,479
P/E Ratio
-
Beta
-
1-Year Change
-61.78%
Shares Outstanding
23,994,725
Next Earnings Date
Nov 18, 2021
What is your sentiment on Trevi Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Trevi Therapeutics Inc News

Trevi Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell

Trevi Therapeutics Inc Company Profile

Trevi Therapeutics Inc Company Profile

Employees
14

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Read More
  • sophia ppayan
    0
    • This one is coming now.
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.